<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <!-- <link rel="stylesheet" href="./css/bootstrap.min.css"> -->
    <!-- <link rel="stylesheet" href="./css/all.min.css"> -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-QWTKZyjpPEjISv5WaRU9OFeRpok6YctnYmDr5pNlyT2bRjXh0JMhjY6hW+ALEwIH" crossorigin="anonymous">
    <link rel="stylesheet" href="./css/style.css">
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/js/bootstrap.bundle.min.js" integrity="sha384-YvpcrYf0tY3lHB60NNkmXc5s9fDVZLESaAA55NDzOxhy9GkcIdslK1eN7N6jIeHz" crossorigin="anonymous"></script>
    <title>Diabetes 360 eMagazine</title>
</head>
<body>
<div class="container p-0">
    <div id="carouselExampleControls" class="carousel slide" data-ride="carousel">
        <div class="carousel-inner">
            <div class="carousel-item active">
                
                <div class="hm-pg bg-color">
                    
                    <div class="bg-pg1-img">
                        <img src="img/PU1.jpg" alt="cover-img">
                    </div>              
                    <div class="cover-header">
                        <img src="./img/Diabetes-360-emagazine.png" alt="magazine-cover">
                    </div>
                    <div class="hm-pg-tail">
                        <div class="cover-bottom justify-content-center d-flex">
                            <div class="row">
                                <div class="col-md-7 col-sm-12 p-99">
                                    <div class="ribbon"><h2>Updates on the Latest Research on Diabetes</h2></div>  
                                    <div class="reference">
                                    <p>Reference</p>
                                    <p>Reference:
                                        1. Lajara R, Heller C, Pantalone KM, Lew E, Li X, Dex T, Kilpatrick CR. iClarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study. Diabetes Obes Metab. 2023
                                    </p>
                                    <p>
                                        2. Misra S, Shukla AK. Teplizumab: type diabetes mellitus preventable? Eur J Clin Pharmacol. 2023 616
                                    </p>
                                    </div> 
                                </div>
                                <div class="card col-md-5 col-sm-12">
                                    <div class="row px-2">
                                        <div class="col">
                                            <div class="card-img">
                                                <img src="./img/magazine-edit-13-3-12.jpg" alt="article">
                                            </div>
                                            <p>iGlarLixi versus Premixed Insulin
                                                in Basal Irsulin Therapy
                                                Advancement<sup>1</sup></p>
                                        </div>
                                        <div class="col">
                                            <div class="card-img">
                                                <img src="./img/magazine-edit-13-3-8.jpg" alt="article">
                                            </div>
                                            <p>Teplizumab's Potential in
                                                Preventing Type 1 Diabetes<sup>2</sup></p>
                                        </div>
                                    </div>
                                
    
                                </div> 
                            </div>                       
                        </div>         
                        <footer class="footer">
                            <div class="pages-header-footer">
                                <div class="row d-flex justify-content-center">
                                    <div class="col-1 p-0">
                                        <div class="pagination justify-content-center align-items-center d-flex">
                                            <p>1</p>
                                        </div>
                                    </div>
                                    <div class="col-7 col-sm-6 align-content-center p-0">
                                        <div class="light-line"></div>
                                    </div>
                                    <div class="col-4 px-0 d-flex justify-content-center align-items-center">
                                        <div class="footer-txt">The 360 e-Magazine</div>
                                    </div>
                                </div>
                            </div>
                        </footer>
                    </div>
                  
                </div>
            </div>
          <div class="carousel-item">
            <div class="d-block w-100">
                <div class="container p-0 bg-color">
                    <div class="main">
                        <div class="circle-0"></div>                       
                            <header class="pages-header-footer p-2">
                                <div class="home-icon">
                                    
                                    <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                                        <img src="./img/home-icon-white.png" alt="">
                                    </a>
                                </div>
                                <div class="row align-items-center p-100 d-flex justify-content-center">
                                    <div class="col-3 header-txt"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                                    <div class="col-6 align-content-center"><div class="light-line"></div></div>
                                    <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-white.png" alt=""></div>
                                </div>
                            </header>
                            <div class="intro">
                                <div class="left-img">
                                    <img src="img/magazine-edit-13-3-2.jpg" alt="newsletter-img">
                                    <div class="circle-1"></div>
                                    <div class="circle-2"><h1>Introduction</h1></div>
                                </div>
                            </div>
                            <div class="body">
                                <div class="intro-header">
                                    <div class="row">
                                        <div class="col-4 align-content-center align-items-center">
                                            <img src="img/360degree-emagazine-logo.png" alt="360degree">
                                        </div>
                                        <div class="col-8">
                                            <h2>Is the first scientific digital magazine sponsored by Sanofi.</h2>
                                        </div>
                                    </div>
                                </div>
                                <div class="para">
                                    <p>
                                        Information presented in <strong>The 360</strong> ... comes from exhaustive search in numerous medical
                                        databases, libraries that encompass numerous sources including more than 50 international
                                        journals from different medical schools—both European and American.
                                    </p>
            
                                    <p>
                                        An editorial team—including physicians, academic researchers and professors as well as medical
                                        writers—screen all medical databases for pertinent and relevant content to build this magazine.
                                    </p>
            
                                    <p><strong>The 360</strong> ... Provides the opportunity to highlight important messages through scientific and
                                        referenced content.</p>
            
                                    <p>
                                        <strong>The 360</strong> ... Is totally independent and does not reflect the opinions of either the publisher nor
                                        the sponsor, making It a highly credible source of information.
                                    </p>
                            </div>
                                <a href="#" class="clickable">Clickable Magazine</a>
                            </div>                                      
                            
                    </div>
                    <div class="sponsors">
                        <div class="row main">
                            <div class="col-8">
                                <div class="row">
                                    <div class="col-6">
                                        <img src="img/ada.png" alt="ada">
                                    </div>
                                    <div class="col-6">
                                        <img src="img/magazine-edit-13-3-3.jpg" alt="">
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        
                <div class="container">
                    <footer class="footer">
                        <div class="pages-header-footer">
                            <div class="row d-flex justify-content-center">
                                <div class="col-1">
                                    <div class="pagination">
                                        <p>2</p>
                                    </div>
                                </div>
                                <div class="col-7 align-content-center p-0">
                                    <div class="dark-line"></div>
                                </div>
                                <div class="col-4 d-flex justify-content-center align-items-center p-0 p-0">
                                    <div class="footer-txt">The 360 e-Magazine</div>
                                </div>
                            </div>
                        </div>
                    
                </footer>
                </div>
            </div>
          </div>
          <div class="carousel-item">
            <div class="d-block w-100">
                <div class="main">                    
                    <header class="pages-header-footer pages-h-f-white">
                        <div class="home-icon">
                            <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                                <img src="./img/home-icon.png" alt="">
                            </a>
                        </div>
                        <div class="row align-items-center p-100 d-flex justify-content-center">
                            <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                            <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                            <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                        </div>
                    </header>
        
                    
                    <div class="table-header">
                        <div class="circle-4"></div>
                        <div class="circle-3"><h1><span class="intro-white">Table</span> <span class="intro-cont">of Content</span></h1></div>   
                        <div class="row table-header-subtext">
                                <div class="line-blue col-7"></div> 
                                <div class="col-12"><h2>Type 2 Diabetes Mellitus</h2></div>                 
                        </div>
                    </div>
                    <div class="table-content">
                        
                        <div class="table-of-content-row">
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-1">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="4"><h3 class="li-header">Type 2 Diabetes Mellitus<span class="page-no">05</span></h3></a></div>
                                    <p>Use of Real-World Data in Population Science to Improve the Prevention and Care of Diabetes-Related Outcomes</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-6">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="5"><h3 class="li-header">Diabetes Subgroups<span class="page-no">06</span></h3></a></div>
                                    <p>Potential Value of Identifying Type 2 Diabetes Subgroups for Guiding Intensive Treatment</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-7">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="6"><h3 class="li-header">Early Glycemic Control<span class="page-no">07</span></h3></a></div>
                                    <p>Effect of Early Glycemic Control in Youth-Onset Type 2 Diabetes</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-8">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="7"><h3 class="li-header">Gla-300 vs. IDegAsp<span class="page-no">08</span></h3></a></div>
                                    <p>Comparative Efficacy of Gla-300 versus IDegAsp in Insulin-naïve Type 2 Diabetes</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-9">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="8"><h3 class="li-header">iGlarLixi Efficacy<span class="page-no">09</span></h3></a></div>
                                    <p>iGlarLixi Time-in-range in Asian Pacific People with Type 2 Diabetes</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-10">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="9"><h3 class="li-header">Glycemic Improvement<span class="page-no">10</span></h3></a></div>
                                    <p>Magnitude of Glycemic Improvement from Basal Insulin in Type 2 Diabetes</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-11">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="10"><h3 class="li-header">Time-in-Range Impact	
                                        <span class="page-no">11</span></h3></a></div>
                                    <p>Time in Range as a Predictor of Microvascular Complications</p>
                                </div>
                            </div>  
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-12">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="11"><h3 class="li-header">iGlarLixi vs. Insulin<span class="page-no">12</span></h3></a></div>
                                    <p>iGlarLixi versus Premixed Insulin in Basal Insulin Therapy Advancement</p>
                                </div>
                            </div>               
                        </div>
                    </div>
                    <footer class="footer">
                        <div class="pages-header-footer">
                            <div class="row d-flex justify-content-center">
                                <div class="col-1 p-0">
                                    <div class="pagination d-flex justify-content-center">
                                        <p>3</p>
                                    </div>
                                </div>
                                <div class="col-7 align-content-center p-0">
                                    <div class="dark-line"></div>
                                </div>
                                <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                    <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                                </div>
                            </div>
                        </div>
                    
                    </footer>
        
                </div>
            </div>
          </div>
          <div class="carousel-item">
            <div class="block w-100">
                <div class="main">                    
                    <header class="pages-header-footer pages-h-f-white">
                        <div class="home-icon">
                            <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                                <img src="./img/home-icon.png" alt="">
                            </a>
                        </div>
                        <div class="row align-items-center p-100 d-flex justify-content-center">
                            <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                            <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                            <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                        </div>
                    </header>
                    <div class="table-header">
                        <div class="circle-4"></div>
                        <div class="circle-3"><h1><span class="intro-white">Table</span> <span class="intro-cont">of Content</span></h1></div>   
                        <div class="row table-header-subtext">
                                <div class="line-blue col-7"></div> 
                                <div class="col"><h2>Type 2 Diabetes Mellitus</h2></div>                 
                        </div>
                    </div>
                    <!-- table 2 -->
                    <div class="table-content"> 
                        <div class="table-of-content-row">
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-13">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="12"><h3 class="li-header">Teplizumab Prevention<span class="page-no">13</span></h3></a></div>
                                    <p>Teplizumab's Potential in Preventing Type 1 Diabetes</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-14">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="13"><h3 class="li-header">A<sub>1c</sub> Variability Outcomes<span class="page-no">14</span></h3></a></div>
                                    <p class="hba">HbA<sub>1c</sub> Variability Impact on Cardiovascular Events</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-15">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="14"><h3 class="li-header">Severe Hypoglycemia Impact<span class="page-no">15</span></h3></a></div>
                                    <p>Hospitalized Hypoglycemia Effects on Mortality Rates</p>
                                </div>
                            </div>
                            <div class="row">
                                <div class="col-3">
                                    <div class="left-decor align-self-center">
                                        <div class="row">
                                            <div class="col-5">
                                                <div class="dotted-circle dotted-circle-16">
                                                </div>
                                            </div>
                                             
                                        </div>
                                    </div>
                                </div>
                                <div class="col-3 align-cntr">
                                    <div class="grey-line align-self-center col-7">
                                        <div class="grey-circle"></div>
                                    </div> 
                                </div>
                                <div class="col-6 d-flex li-article align-self-center flex-column">
                                    <div class="d-flex align-items-center"><a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="15"><h3 class="li-header">Heart Failure Risk<span class="page-no">16</span></h3></a></div>
                                    <p>Analyzing Heart Failure Risk in Type 1 Diabetes</p>
                                </div>
                            </div>           
                        </div>
                    </div>
                    <p>HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub></p>
                    <footer class="footer">
                        <div class="pages-header-footer">
                            <div class="row d-flex justify-content-center">
                                <div class="col-1 p-0">
                                    <div class="pagination d-flex justify-content-center">
                                        <p>4</p>
                                    </div>
                                </div>
                                <div class="col-7 align-content-center p-0">
                                    <div class="dark-line"></div>
                                </div>
                                <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                    <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                                </div>
                            </div>
                        </div>
                    
                    </footer>
        
                </div>
            </div>
          </div>
          <div class="carousel-item">
            <div class="main">
                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="bold category primary-col">Type 2 Diabetes Mellitus</h1>
                    <h1 class="headline"><span class="bold">Use of Real-World Data in Population Science to Improve the Prevention and Care of Diabetes-Related Outcome</span></h1>
                    <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Gregg EW, Patorno E, Karter AJ, Mehta R, Huang ES, White M, Patel CJ, McElvaine AT, Cefalu WT, Selby J, Riddle MC, Khunti
                            K. Use of Real-World Data in Population Science to Improve the Prevention and Care of Diabetes-Related Outcomes. Diabetes
                            Care. 2023 Jul 1326-1316:(7)46;1. doi: 10.2337/ dc1438-22.</p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-16.jpg" alt="feature-img">
                            </div>
                            <p>The past decade of population research for diabetes has
                                seen a dramatic proliferation of the use of real-world
                                data (RWD) and real-world evidence (RWE) generation
                                from non-research settings, including both health and
                                non-health sources, to influence decisions related to
                                optimal diabetes care.</p>
                                <p>
                                    A common feature of these new data is that they were
                                    not collected for research purposes, but can enrich
                                    information about individual characteristics, risk factors,
                                    interventions, and health effects.
                                </p>
                                <p>
                                    This expanded the role of sub-disciplines such as
                                    comparative effectiveness research and precision
                                    medicine, new quasi-experimental study design, new
                                    research platforms such as distributed data networks,
                                    and new statistical methods for clinical prediction of
                                    prognosis and treatment response.
                                </p>
            
                                <p>
                                    The result of these developments is a greater potential
                                to progress diabetes treatment and prevention through
                                the increasing range of populations, interventions,
                                outcomes, and settings that can be efficiently examined.
                                However, this spread also increases the threat of bias
                                and misleading results. The level of evidence derived
                                from RWD is ultimately determined by the quality of
                                the data and the rigorous application of research design
                                and analysis.
                                </p>
            
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                In this report, Gregg et al reviewed the current landscape
                                and applications of RWD in clinical effectiveness and
                                population health research for diabetes. The authors
                                then summarized opportunities and best practices in the
                                conduct, reporting, and dissemination of information
                                derived from RWD to optimize its value and limit its
                                drawbacks.
                            </p>
                            <p>
                                RCTs demonstrate necessary causal evidence of efficacy;
                                however, they are typically costly, take a long time to
                                be conducted, expose participants to experimentation,
                                and are usually designed to answer a narrow hypothesis
                                in highly selected populations. Thus, they cannot fully
                                ensure that, once launched, the intervention will be
                                effective and safe in practice for a wider population. RWE
                                can help provide additional complementary evidence of
                                effectiveness and safety.
                            </p>
                            <p>
                                RWE obtained from analysis of more representative RWD
                            is becoming more and more relevant and significant for
                            a chronic nontransmissible disease such as diabetes,
                            and its application has grown over the past few years. It
                            is frequently used to supplement RCT results in clinical
                            effectiveness research, with the main benefits being low
                            cost and higher external validity.
                            </p>
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    RWD are increasingly regarded as essential sources
                                    of data for regulatory purposes, have an impact on
                                    clinical recommendations and decision-making,
                                    and even help to expand the therapeutic indications
                                    for medications.
                                    RWD have also been utilized in studies on primary
                                    prevention, health economics, and populationlevel
                                    research on health care, including natural
                                    experiments and long-term surveillance and
                                    monitoring.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        RWD, real-world data; RCT, randomized controlled trial; RWE, real-world evidence
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>5</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">
                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">Potential Value of Identifying Type 2 Diabetes
                        Subgroups for Guiding Intensive Treatment:</span>
                        A Comparison of Novel Data-Driven Clustering with
                        Risk-Driven Subgroups</h1>
                    <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Li X, van Giessen A, Altunkaya J, Slieker RC, Beulens JWJ, ‘t Hart LM, Pearson ER, Elders PJM, Feenstra TL, Leal J. Potential
                            Value of Identifying Type 2 Diabetes Subgroups for Guiding Intensive Treatment: A Comparison of Novel Data- Driven Clustering with
                            Risk-Driven Subgroups. Diabetes Care. 2023 Jul 1;46(7):1395-1403. doi: 10.2337/dc22-2170.</p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-17.jpg" alt="feature-img">
                            </div>
                            <p>Li et al aimed to estimate the impact on lifetime health
                                and economic outcomes of different methods of
                                stratifying individuals with type 2 diabetes, followed by
                                guideline-based treatment intensification targeting
                                BMI and LDL in addition to HbA<sub>1c</sub>.</p>
                                <p>
                                    The authors divided 2,935 newly diagnosed individuals
        from the Hoorn Diabetes Care System (DCS) cohort
        into five Risk Assessment and Progression of Diabetes
        (RHAPSODY) data-driven clustering subgroups (based
        on age, BMI, HbA<sub>1c</sub>, C-peptide, and HDL) and four riskdriven
        subgroups by using fixed cutoffs for HbA<sub>1c</sub> and
        risk of cardiovascular disease based on guidelines.
                                </p>
                                <p>
                                    The UK Prospective Diabetes Study Outcomes Model 2
        estimated discounted expected lifetime complication
        costs and quality-adjusted life-years (QALYs) for
        each subgroup and across all individuals. Gains from
        treatment intensification were compared with care
        as usual as observed in DCS. A sensitivity analysis was
        conducted based on Ahlqvist subgroups.
                                </p>
            
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>To help decision making, the authors expressed their
                                results as the maximum annual price in U.S. and U.K.
                                settings that can be spent in the health care sector for
                                identification and treatment of a certain subgroup while
                                remaining cost-effective.
                            </p>
                            <p>
                                This straightforward indicator informs clinicians and
        decision makers on whether intensifying treatment
        is beneficial and cost-effective. Under care as usual,
        prognosis in the RHAPSODY data-driven subgroups
        ranged from 7.9 to 12.6 QALYs. Prognosis in the risk-driven
        subgroups ranged from 6.8 to 12.0 QALYs. Compared
        with homogenous type 2 diabetes, treatment for
        individuals in the high-risk subgroups could cost 22.0%
        and 25.3% more and still be cost effective for data-driven
        and risk-driven subgroups, respectively. Targeting BMI
        and LDL in addition to HbA<sub>1c</sub> might deliver up to 10-fold
        increases in QALYs gained.
                            </p>
                            <p>
                                Thus, the results showed that the data-driven subgroups
        were able to stratify individuals with diverse prognosis,
        displaying significant differences in simulated lifetime
        QALYs and complication costs.
                            </p>
                            <p>
                                However, the risk-driven subgroups showed somewhat
        larger differences between high- and low-risk subgroups
        compared with the data-driven subgroups.
                            </p>
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    Risk-driven subgroups better discriminated
        prognosis. <br>
        Both stratification methods supported
        stratified treatment intensification, with
        the risk-driven subgroups being somewhat
        better in identifying individuals with the most
        potential to benefit from intensive treatment.
        Irrespective of stratification approach, better
        cholesterol and weight control showed
        substantial potential for health gains.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        BMI, body mass index; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; LDL, low density lipoprotein;
        HDL, high density lipoprotein; DCS, hoorn diabetes care system; QALYs,
        quality-adjusted life-years
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>6</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">
                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">Effect of Early Glycemic Control in Youth-Onset Type 2
                        Diabetes on Longer-Term Glycemic Control and ß-Cell
                        Function:</span>
                        Results from the TODAY Study<sup>1</sup></h1>
                        <hr>
                    <div class="subheader">
                        <p class="primary-col">Sources:
                            1- TODAY Study Group. Effect of Early Glycemic Control in Youth-Onset Type 2 Diabetes on Longer-Term Glycemic Control and ß-Cell
                            Function: Results From the TODAY Study. Diabetes Care 2023 Aug 1;46(8):1507-1514. doi: 10.2337/dc23- 0560. PMID: 37378967.
                            2- Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care. 2013
                            Jun;36(6):1775-6. doi: 10.2337/dc13-0707.</p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-18.jpg" alt="feature-img">
                            </div>
                            <p>The primary results of the TODAY study, demonstrated
                                that T2D may have a much more aggressive course in
                                youth, with approximately half of patients unable to
                                maintain glycemic control on metformin monotherapy
                                despite good medication compliance. The data on
                                insulin resistance and secretion derived from serial oral
                                glucose tolerance tests in the TODAY study suggested
                                early and rapid deterioration of ß-cell function in
                                these youth compared with data published on adult
                                individuals with newly diagnosed T2D. These data
                                suggested the need to intervene aggressively and early
                                in youth<sup>2</sup>.</p>
                                <p>
                                    The overall goal of this analysis was to address the
        hypothesis that tight early glycemic control (first 6
        months after randomization), independent of initial
        insulin sensitivity and secretion, would predict better
        long-term (2–9 years after randomization) ß-cell
        function and glycemic control in participants with
        youth onset type 2 diabetes from the TODAY study<sup>1</sup>.
                                </p>
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                To this end, the investigators performed oral glucose
        tolerance tests longitudinally through year 9 to derive
        estimates of insulin sensitivity and secretion. Early
        glycemia was defined by mean HbA<sub>1c</sub> during the first 6
        months post-randomization, categorized into five HbA<sub>1c</sub>
        groups (&lt;5.7%, 5.7 to &lt;6.4%, 6.4 to &lt;7.0%, 7.0 to &lt;8.0%,
        and ≥8.0%). The long-term period was defined as the
        period between years 2 and 9<sup>1</sup>.
                            </p>
                            <p>
                                A total of 656 participants (64.8% female, baseline
        mean age 14 years, diabetes duration &lt;2 years) had
        longitudinal data available over an average of 6.4 ± 3.2
        years of follow-up<sup>1</sup>.
                            </p>
                            <p>
                                HbA<sub>1c</sub> significantly increased in all early glycemic groups
        during years 2-9, with a steeper increase (+0.40%/year)
        among participants with the tightest initial control
        (mean early HbA<sub>1c</sub>&lt;5.7%), in parallel to a decline in the
        C-peptide-derived disposition index<sup>1</sup>.
        Nevertheless, the lower HbA<sub>1c</sub> categories continued to
        have relatively lower HbA<sub>1c</sub> over time<sup>1</sup>.
                            </p>
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    Thus, even in the three categories of youth
        where ADA guidelines for glycemic control
        (HbA<sub>1c</sub> &lt;7.0%) were initially met or exceeded,
        ß-cell failure still progressed.1
        HbA<sub>1c</sub>
         increased most quickly in the group
        with the lowest level of glycemia (HbA<sub>1c</sub>
        &lt;5.7%),
        demonstrating that even very tight early
        glycemic control alone does not improve the
        trajectory of diabetes control in the long run.1
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        RWD, real-world data; RCT, randomized controlled trial; RWE, real-world evidence
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>7</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">     
        <header class="pages-header-footer pages-h-f-white">
            <div class="home-icon">
                <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                    <img src="./img/home-icon.png" alt="">
                </a>
            </div>
            <div class="row align-items-center p-100 d-flex justify-content-center">
                <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
            </div>
        </header>
        <div class="article-head">
            <h1 class="headline">
                <span class="bold">
                    Comparative Efficacy and Safety of Gla 300 versus
IDegAsp in Insulin-naïve People with Type 2 Diabetes
Mellitus Uncontrolled on Oral Anti-diabetics
            </span> </h1>
                <hr>
                <div class="subheader">
                    <p class="primary-col">
                        Source: Ritzel R, Ghosh S, Emral R, Malek R, Zeng L, Mabunay MA, Landgraf W, Guyot P, Serafini P, Pushkarna D, Malik RA. Comparative
efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15121.
                    </p>
                </div>
        </div>
        <article>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    <div class="feature-img">
                        <img src="./img/magazine-edit-13-3-19.jpg" alt="feature-img">
                    </div>
                    <p>
                        Insulin glargine injection is a long-acting secondgeneration
                        basal insulin containing 300 units/ml of
                        insulin glargine (Gla-300). Randomized controlled trial
                        (RCT) evidence showed an improved pharmacokinetic
                        and pharmacodynamic profile of Gla-300 compared with
                        Gla-100, with a lower risk of hypoglycemia and slightly
                        less weight gain. Insulin degludec and insulin aspart
                        (IDegAsp) injection 70/30 is a premixed combination of
                        a long-acting second-generation basal insulin analogue
                        and a rapid-acting human insulin analogue. RCT
                        evidence comparing IDegAsp once daily with Gla-100
                        found a similar reduction in HbA<sub>1c</sub> and fasting plasma
                        glucose (FPG), but confirmed anytime hypoglycemia
                        was higher with IDegAsp once daily while confirmed
                        nocturnal hypoglycemia was higher with Gla-100.
                    </p>
                        <p>
                            Ritzel et al., aimed to compare the efficacy and safety
of Gla-300 with insulin IDegAsp once daily in patients
with type 2 diabetes (T2D) inadequately controlled on
oral anti-diabetic drugs (OADs).
                        </p>
                        <p>
                            A systematic literature review of randomized controlled
                            trials was followed by an indirect treatment comparison
                            5 of studies involving insulin naïve adults, inadequately
                            controlled [glycated hemoglobin (HbA<sub>1c</sub>) ≥7.0%] on
                            OADs, who received Gla-300 or IDegAsp once daily. The
                            outcomes of interest included change in HbA<sub>1c</sub>, blood
                        </p>

    
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <p>
                        glucose, weight and insulin dose, as well as incidence
and event rate of hypoglycemia and other adverse
events.
                    </p>
                    <p>
                        Four trials with broadly similar baseline patient
characteristics were included in the meta-analyses
and indirect treatment comparison. At 24-28 weeks,
the indirect comparison of Gla-300 to IDegAsp once
daily estimated no statistically significant difference for
change in HbA<sub>1c</sub> (%) from baseline [mean difference of
0.10% (95% CI: -0.20, 0.39; p=.52)]; a statistically significant
mean difference of -1.31 kg (95% CI: -1.97, -0.65; p&lt;.05)
for change in body weight from baseline; statistically
significant odds ratios of 0.62 (95% CI: 0.41, 0.93; p&lt;.05)
for incidence of any hypoglycemia; and 0.47 (95% CI:
0.25, 0.87; p&lt;.05) for incidence of anytime confirmed
hypoglycemia (plasma glucose &lt;3.0-3.1 mmol/L). No
significant differences were observed for insulin dose
and adverse events.
                    </p>
                    <p>
                        RWE obtained from analysis of more representative RWD
                    is becoming more and more relevant and significant for
                    a chronic nontransmissible disease such as diabetes,
                    and its application has grown over the past few years. It
                    is frequently used to supplement RCT results in clinical
                    effectiveness research, with the main benefits being low
                    cost and higher external validity.
                    </p>
                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            This ITC shows no significant difference in
change in HbA<sub>1c</sub> and insulin dose at 24- 28 weeks
between Gla-300 and IDegAsp once daily.
However, Gla-300 was associated with less
weight gain and a lower risk of clinically
significant confirmed (PG &lt;3.0-3.1 mmol/L)
hypoglycemia and any hypoglycemia compared
with IDegAsp once daily.
There were differences in SMPG levels between
the two treatments. These findings suggest that
insulin- naïve patients with T2D inadequately
controlled on OADs commencing Gla-300
would probably experience less weight gain
and have a lower risk of clinically significant
hypoglycemia (PG &lt;3.0-3.1 mmol/L) compared
with commencing IDegAsp.
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                RCT, randomized controlled trial; ITC, indirect treatment comparison;
PG, plasma glucose; SMPG, self-monitored plasma glucose; T2D, type 2
diabetes; OADs, oral antidiabetic drugs
                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
            </div>
            <footer class="footer">
                <div class="pages-header-footer">
                    <div class="row d-flex justify-content-center">
                        <div class="col-1 p-0">
                            <div class="pagination d-flex justify-content-center">
                                <p>8</p>
                            </div>
                        </div>
                        <div class="col-7 align-content-center p-0">
                            <div class="dark-line"></div>
                        </div>
                        <div class="col-4 d-flex justify-content-center align-items-center p-0">
                            <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                        </div>
                    </div>
                </div>
            
        </footer>
          </div>          
          <div class="carousel-item">
            <div class="main">                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">iGlarLixi Provides a Higher Derived Time-in-range
                        versus Insulin Glargine 100 U/mL or Lixisenatide in Asian
                        Pacific People with Type 2 Diabetes:</span>
                        A Post Hoc Analysis</h1>
                        <hr>
                    <div class="subheader">
                        <p class="primary-col">
                            Source: Guo X, Yang W, Zhang J, Dong X, Liu M, Gu S, Lauand F, Li L, Huang Q, Kang L, Souhami E. iGlarLixi provides a higher derived
                            time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes:<br>
                            A post hoc analysis. Diabetes Obes Metab. 2023 Jul;25(7):2005-2011.
                        </p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-20.jpg" alt="feature-img">
                            </div>
                            <p>
                                Guo et al., aimed to evaluate the efficacy of iGlarLixi
                                (insulin glargine 100 units/mL / lixisenatide) in the Asian
                                Pacific (AP) population with type 2 diabetes (T2D) using
                                dTIRs calculated from seven-point self measured blood
                                glucose.
                            </p>
                               
                            <h3 class="h3-inner">Two phase III trials were analyzed.</h3>
                                <p>
                                    - The participants of the LixiLan-O-AP (NCT03798054)
                                    and LixiLan-LCN (NCT03798080) studies were included.<br>
                                    - In the LixiLan-O-AP study (n=878), insulin-naive AP
                                    patients (86.3% of whom were from mainland China)
                                    with suboptimally controlled T2D were randomized
                                    (2:2:1) to receive iGlarLixi, iGlar or Lixi once a day on top
                                    of continued metformin with or without sodium-glucose
                                    co-transporter-2 inhibitors.<br>
                                    - The LixiLan-LCN study (n=426) included Chinese patients
                                    with T2D uncontrolled on basal insulin, randomized (1:1)
                                    to iGlarLixi or iGlar on top of continued metformin if
                                    applicable.<br>
                                    - Changes in derived time-in-ranges from baseline to endof-
                                    treatment (EOT) and estimated treatment differences
                                    (ETDs) were analyzed.
                                </p>
        
            
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                - The proportions of patients achieving 70% or higher
                                derived time-in-range (dTIR), 5% or higher dTIR
                                improvement, and the composite triple target (≥70%
                                dTIR, &lt;4% derived time-below-the-range [dTBR] and
                                &lt;25% derived timeabove- the-range [dTAR]) were
                                calculated.
                            </p>
                            <p>
                                iGlarLixi achieved greater improvements in derived
                                time-in-ranges than iGlar or Lixi without increasing
                                the risk of hypoglycaemia. The results of this post hoc
                                analysis, in addition to previous results of the LixiLan
                                study programme, support the use of iGlarLixi as an
                                efficacious option for both insulin-naive and basal
                                insulinexperienced AP people with suboptimally
                                controlled T2D.
                            </p>
                            
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    This post hoc analysis showed that iGlarLixi is
                                    an effective treatment option to improve
                                    dTIR and dTTR in insulin-naïve and insulinexperienced
                                    AP people with T2D. <br>
                                    The proportions of patients achieving 70% or
                                    higher dTIR, 5% or higher dTIR improvement
                                    and the triple target were higher with iGlarLixi
                                    than with iGlar or Lixi.<br>
                                    In addition, iGlarLixi reduced dTAR without
                                    increasing hypoglycemic exposure, as indicated
                                    by the low dTBR values. The insulin glargine
                                    component of iGlarLixi ensures glucose
                                    control in the fasting state and at night, while
                                    the lixisenatide component decreases the
                                    postprandial excursions.<br>
                                    This analysis showed that iGlarLixi increased
                                    the proportion of patients with 70% or higher
                                    dTIR to achieve glycemic goals.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        T2D, type 2 diabetes; AP, Asian pacific; dTIR, derived time-in-range;
                                        dTBR, derived time-below-range; dTAR, derived time-above-range
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>9</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">Magnitude of Glycemic Improvement in Patients with
                        Type 2 Diabetes Treated with Basal Insulin:</span>
                        Subgroup Analyses from the MOBILE Study</h1>
                        <hr>
                    <div class="subheader">
                        <p class="primary-col">
                            Source: Davis G, Bailey R, Calhoun P, Price D, Beck RW. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated
                            with Basal Insulin: Subgroup Analyses from the MOBILE Study. Diabetes Technol Ther. 2022 May;24(5): 324-331
                        </p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            
                            <p>
                                The recent multicenter MOBILE clinical trial showed that
        sustained use of real-time CGM (CGM) in participants with
        type 2 diabetes treated with basal insulin in combination
        with other noninsulin agents in a primary care setting
        improved glycemic control during 8 months of follow-up.
        Both HbA<sub>1c</sub> and mean glucose values after 8 months were
        lower for participants using CGM compared to those using
        self-monitoring of blood glucose with a blood glucose
        meter (BGM). To further evaluate the magnitude of the
        effect of CGM on glycemic control among adults with
        poorly controlled type 2 diabetes treated with basal insulin,
        Davis et al., examined data from the MOBILE trial stratified
        according to underlying glycemic control metrics at
        baseline. The investigators hypothesized that participants
        with worse control at baseline (by HbA<sub>1c</sub> and CGM timein-
        range 70–180 mg/dL [TIR] categories) would have the
        greatest benefit from adding CGM to their diabetes care
        over 8 months of follow-up.
                            </p>
                                <p>
                                    To this end, they conducted a post hoc analysis of the
        MOBILE Study, a multicenter trial examining the impact
        of CGM versus self-monitoring with a blood glucose meter
        (BGM) in patients with type 2 diabetes treated with basal
        insulin without prandial insulin.
                                </p>
                                <p>
                                    As previously reported, the MOBILE trial included 175 adults
        with type 2 diabetes using basal insulin, with 116 randomly
        assigned to the CGM group and 59 to the BGM group. Mean
        age was 57 years (range 33 to 79); 50% were female. The
        race/ethnicity distribution was 47% white, 28% Hispanic, 18%
        black, 5% Asian, and 2% other. Mean (±standard deviation
        [SD]) baseline HbA<sub>1c</sub> was 9.1% ± 0.9% and mean (±SD) baseline
        TIR 70–180 mg/dL was 40% ± 25%. Potential participants were
        recruited from primary care practices and were not under
        the care of an endocrinologist to manage their diabetes.
                                </p>
            
                                <p>
                                    Participants could not have been using prandial insulin
        at the time of enrollment. Participants were divided into
        subgroups based on baseline hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) and
        baseline time-in-range 70-180 mg/dL (TIR). Change in TIR
        from baseline was calculated within each subgroup.
                                </p>
        
                                <p>
                                    In subgroups based on baseline HbA<sub>1c</sub>, compared with the
        BGM group, the CGM group had 14% greater increase in
        TIR for participants with baseline HbA<sub>1c</sub> ≥8.5%, 14% greater
        increase for baseline HbA<sub>1c</sub> ≥9.0%, 22% greater increase for
                                </p>
                                
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                baseline HbA<sub>1c</sub> ≥9.5%, and 32% greater increase for baseline
        HbA<sub>1c</sub> ≥10.0% (P-value for interaction = 0.27).
                            </p>
                            <p>
                                The time spent with glucose >250 mg/dL was significantly
        lower with CGM compared with BGM among participants
        with higher HbA<sub>1c</sub> values (P for interaction = 0.004). Results
        in subgroups based on baseline TIR paralleled the results in
        subgroups based on baseline HbA<sub>1c</sub>.
                            </p>
                            <p>
                                Mean glucose over 24 h by baseline HbA<sub>1c</sub>. For those with
        baseline HbA<sub>1c</sub> &lt;8.5%, mean glucose at baseline was 169 mg/
        dL in the CGM and BGM groups. For those with baseline
        HbA<sub>1c</sub> 8.5% to &lt;9.5%, mean glucose at baseline was 203 and
        206 mg/dL in the CGM and BGM groups, respectively. For
        those with baseline HbA<sub>1c</sub> ≥9.5%, mean glucose at baseline
        was 242 and 245 mg/dL in the CGM and BGM groups,
        respectively.
                            </p>
        
                            <p>
                                This post hoc analysis of the MOBILE trial demonstrated
        that among participants with worse glycemic control at
        baseline, the use of CGM was associated with a substantial
        increase in TIR and reduction in HbA<sub>1c</sub> compared with use
        of BGM alone. The most remarkable benefit from CGM in
        those with the highest baseline HbA<sub>1c</sub> values appears to be
        a reduction in time spent with glucose values exceeding
        250 mg/dL.
                            </p>
        
        
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    While the benefit of CGM on TIR among
        patients with type 2 diabetes treated with
        basal insulin is apparent across the range of
        baseline glycemic control, the greatest impact
        of CGM is in those with the worst baseline
        glycemic control, particularly among those
        with HbA<sub>1c</sub> ≥10%.
        Overall, the findings of this post hoc analysis
        suggest trends of greater treatment effect
        on glycemic control outcomes with CGM
        compared with BGM in those with worse
        baseline glycemic control, similar to what
        has been observed with other therapeutic
        interventions. It is possible that behavior
        modifications prompted by real-time glucose
        data can provide significant additive glycemic
        control benefit among patients with very high
        initial HbA<sub>1c</sub> on less intensive insulin regimens.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        BGM, blood glucose meter; CGM, continuous glucose monitoring; HbA<sub>1c</sub>,
        hemoglobin A<sub>1c</sub>; TIR, time-in-range
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>10</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>          
          <div class="carousel-item">
            <div class="main">        
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
        <div class="article-head">
            <h1 class="headline"><span class="bold">
                Time in Range, as Measured by Continuous Glucose
Monitor, as a Predictor of Microvascular Complications
in Type 2 Diabetes:
            </span>
            A Systematic Review</h1>
                <hr>
            <div class="subheader">
                <p class="primary-col">
                    Source: Raj R, Mishra R, Jha N, Joshi V, Correa R, Kern PA. Time in range, as measured by continuous glucose monitor, as a predictor
                    of microvascular complications in type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. 2022 Jan;10(1):e002573.
                </p>
            </div>
        </div>
        <article>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    <div class="feature-img">
                        <img src="./img/magazine-edit-13-3-21.jpg" alt="feature-img">
                    </div>
                    <p>
                        Continuous glucose monitoring (CGM)-derived time in
range (TIR) correlates with hemoglobin A<sub>1c</sub> (A<sub>1c</sub>) among
patients with type 2 diabetes mellitus (T2DM); however,
there is a paucity of data evaluating its association with
microvascular complications. Raj et al., conducted this
systematic review to examine the association between TIR
and microvascular complications of diabetic retinopathy
(DR), diabetic nephropathy (DN), and diabetic peripheral
neuropathy (DPN).
                    </p>
                        <p>
                            This systematic review, which included 11 studies
                            with more than 13987 patients, provided insight into
                            associations of diabetic nephropathy, diabetic peripheral
                            neuropathy, and diabetic retinopathy with time in range
                            among patients with type 2 diabetes.
                        </p>
                        <p>
                            For the purpose of analysis, Raj et al., performed a
comprehensive literature search of the PubMed, Scopus,
and Web of Science databases on June 5, 2021, for studies
published from 2010 to June 2021. For inclusion, studies
needed to be published in English. Search terms used
in the query included continuous glucose monitor,
continuous glucose monitoring, Dexcom, Freestyle Libre,
Guardian, flash glucose monitoring, time in range, timein-
range, or TIR, diabetes complications, microvascular
complications, retinopathy, neuropathy, nephropathy,
complication, microalbuminuria, or albuminuria, and
type II diabetes or type 2 diabetes. The initial search
identified 110 publications for possible inclusion.

                        </p>
    
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <p>
                        After exclusion of duplicates and further screening, a
group of 11 articles were identified for inclusion in the
systematic review. These 11 studies included a population
of 13,987 patients, with a median sample size of 466
(range: 105- 5901, IQR: 616). Of the 11 included, 10 were
cross sectional in design and the remaining study was an
interim analysis of an ongoing prospective observational
study. The study population had a mean of 59.3 (SD, 1.3)
years, the mean HbA<sub>1c</sub> at baseline was 8.2% (SD, 0.5%), and
the mean duration of diabetes was 11.3 (SD, 1.0) years.
                    </p>
                    <p>
                        A group of 4 studies examined the association between
time in range and diabetic retinopathy. In these 4
studies, results indicated a 10% increase in time in range
was associated with a reduction in severity of diabetic
retinopathy and increased time spent in target range
was associated with a decrease in the severity of diabetic
retinopathy. Investigators also pointed out time-inrange
was similar to HbA<sub>1c</sub> for predicting diabetic retinopathy in
patients with type 2 diabetes.
                    </p>
                    <p>
                        Similarly, a group of 4 studies examined the association
between time-in-range and diabetic nephropathy.
In these studies, a 10% increase in time-in-range was
associated with a decrease in albuminuria. Additionally, a
single study demonstrated increased time-in-range was
associated with a lower risk of macroalbuminuria and
diabetic kidney disease.
                    </p>
                    <p>
                        A total of 7 studies assessed the relationship between
time-in-range and diabetic neuropathy while 4 studies
examined time-in-range and diabetic painful neuropathy.
                    </p>
                    <p>
                        Analysis of these studies indicated increased time-inrange
was associated with a decrease in the prevalence
and severity of diabetic painful neuropathy and
cardiovascular autonomic neuropathy.
                    </p>
                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            This study affirms the significant association
between CGM-derived TIR and microvascular
complications of diabetic nephropathy, diabetic
retinopathy, and diabetic painful neuropathy
among patients with type 2 diabetes mellitus
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                SD, standard deviation; HbA<sub>1c</sub>
                                , hemoglobin A<sub>1c</sub>; CGM, continuous glucose
                                monitoring; TIR, time-in-range                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
            </div>
            <footer class="footer">
                <div class="pages-header-footer">
                    <div class="row d-flex justify-content-center">
                        <div class="col-1 p-0">
                            <div class="pagination d-flex justify-content-center">
                                <p>11</p>
                            </div>
                        </div>
                        <div class="col-7 align-content-center p-0">
                            <div class="dark-line"></div>
                        </div>
                        <div class="col-4 d-flex justify-content-center align-items-center p-0">
                            <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                        </div>
                    </div>
                </div>
            
        </footer>
            </div>
          <div class="carousel-item">
            <div class="main">                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">iGlarLixi versus Premixed Insulin Initiation in Adults
                        with Type 2 Diabetes Advancing from Basal Insulin
                        Therapy:</span>
                        The SoliComplex Real-world Study</h1>
                        <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Lajara R, Heller C, Pantalone KM, Lew E, Li X, Dex T, Kilpatrick CR. iGlarLixi versus premixed insulin initiation in adults with type
                            2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study. Diabetes Obes Metab. 2023 May;25(5):1249-1260</p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-22.jpg" alt="feature-img">
                            </div>
                            <p>
                                Premixed insulin is typically taken twice day, though
        additional injections may be added based on the
        needs of each patient’s treatment. Premixed insulin is
        frequently used to moderate increases in postprandial
        glucose excursions in patients who have inadequate
        control following oral or basal insulin therapy. It is
        especially useful for patients who have regular eating
        patterns and who need to streamline their treatment.
                            </p>
                            <p>iGlarLixi, a fixed-ratio combination therapy comprising
                                insulin glargine 100 U/ml and the glucagon-like
                                peptide-1 receptor agonist (GLP-1 RA) lixisenatide, is a
                                once-daily alternative to premixed insulin. Lajara et al.,
                                reported the results of a real-world observational study
                                conducted to compare treatment persistence in adults
                                with T2D suboptimally controlled with basal insulin
                                who initiated therapy with either iGlarLixi or a premixed
                                insulin regimen. Treatment adherence, change in HbA<sub>1c</sub>,
                                hypoglycemia events, and all-cause, diabetes-related
                                and hypoglycemia-related HRU and healthcare costs at
                                12 months were also assessed as secondary endpoints.
                                Subgroup analyses assessed outcomes in people aged
                                65 years or older, and in those who had a baseline HbA<sub>1c</sub>
                                of 9% or higher.
                            </p>
                            <p>
                                Data from adults (age ≥ 18 years) with T2D who had
                            </p>
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                previously received basal insulin and newly initiated
        iGlar-Lixi or premixed insulin were used for this
        retrospective real-world analysis. Using a greedy nearest
        neighbor matching algorithm, cohorts were propensityscore
        matched based on baseline characteristics, and
        outcomes were evaluated after 12 months. For people
        65 years of age or older and those whose baseline HbA<sub>1c</sub> was 9% or higher, subgroup analyses were conducted.
                            </p>
                            <p>
                                Treatment persistence across the population was
        the main outcome. Treatment adherence, healthcare
        resource use (HRU), costs, hypoglycemia events, and
        change in HbA<sub>1c</sub> from baseline were secondary endpoints.
        There were 834 participants in each cohort. Treatment
        persistence was statistically significantly higher for
        iGlarLixi than premixed insulin in the general population
        at 12 months: 42.5% versus 39.1%; hazard ratio 0.88; 95%
        confidence interval 0.778-0.998; p=.0465. Adherence and
        HbA<sub>1c</sub> reduction were comparable between groups, but
        iGlarLixi had numerically lower rates of hypoglycemia
        events, HRU, and costs. Results in the subgroup of
        people 65 years of age or older as well as those with an
        HbA<sub>1c</sub> of 9% or higher were comparable to those for the
        general population.
                            </p>
                            
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    The results of this retrospective, realworld
        observation study in adults with T2D
        suboptimally controlled on basal insulin
        showed that once-daily iGlarLixi is an effective
        treatment alternative to premixed insulin,
        with significantly higher although probably
        clinically similar treatment persistence,
        similar adherence and HbA<sub>1c</sub> reduction, and
        numerically lower hypoglycemia events, HRU
        and costs. As the results from the overall
        population were replicated in the subgroup
        aged 65 years or older, as well as those with
        a baseline HbA<sub>1c</sub> of 9% or higher, iGlarLixi can
        also be considered an appropriate treatment
        simplification option for older adults with T2D
        that is suboptimally controlled on basal insulin,
        who need a regimen with a low associated risk
        of hypoglycemia and improved simplicity with
        once-daily administration.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        T2D, type 2 diabetes; HbA<sub>1c</sub>, hemoglobin A<sup>1c</sup>; HRU, healthcare resource utilization.
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>12</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">Teplizumab: Type 1 Diabetes Mellitus Preventable?</span>
                    </h1>
                        <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Misra S, Shukla AK. Teplizumab: type 1 diabetes mellitus preventable? Eur J Clin Pharmacol. 2023 May;79(5):609- 616. doi:
                            10.1007/s00228-023-03474-8.</p>
                    </div>
                </div>
                <article>
                    <div class="col-12">
                        <div class="feature-img">
                            <img src="./img/magazine-edit-13-3-6.jpg" alt="feature-img">
                        </div>
                    </div>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            
                            <p>
                                Type 1 diabetes mellitus (T1DM) is an autoimmune
                                condition driven by T lymphocytes that specifically
                                declines the function of beta cells of pancreas.
                                Immunological treatments aim to stop this decline in
                                ß-cell function thus preventing TIDM. Although TIDM
                                occur at any age, it is one of the most common chronic
                                disorders in children. T1DM accounts for 5 to 10% of all
                                cases of diabetes amounting 21-42 million affected
                                persons. Teplizumab is a novel drug recently approved
                                by the US FDA for the treatment of T1DM.
                            </p>
        
                            <p>This drug reduces abnormal glucose tolerance who are
                                at high risk for developing T1DM and have antibodies
                                suggesting an immunological attack on their pancreas.
                                A 14-day infusion of the drug prevents T cells’ attack
                                of the insulin-producing cells of the pancreas. Adverse
                                events due to teplizumab reported so far mild and of
                                limited duration.
                            </p>
                            <p>This review gave an overview of the preclinical and clinical
                                research on teplizumab for their role in new-on-set T1DM.
                            </p>
                            <p>T1DM, type 1 diabetes mellitus; FDA, Food and Drug Administration</p>
            
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    A 14-day infusion of teplizumab, an anti-CD3
                                    immunotherapy, prevents T cells’ attack of the
                                    insulin-producing cells of the pancreas.<br>
                                    Drug has been found to be effective in
        preclinical and clinical studies. It was shown
        to improve the metabolic responses and delay
        the onset of diabetes Adverse events due to
        teplizumab reported so far mild and of limited
        duration. Evidence from metanalyses and
        other randomized controlled trials (RCT) show
        that teplizumab treatment preserves insulin
        production and reduces the use of exogenous
        insulin in some patients with new-onset T1DM.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        T1DM, type 1 diabetes mellitus; FDA, Food and Drug Administration
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>13</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">
               <header class="pages-header-footer pages-h-f-white">
                <div class="home-icon">
                    <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                        <img src="./img/home-icon.png" alt="">
                    </a>
                </div>
                <div class="row align-items-center p-100 d-flex justify-content-center">
                    <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">
                        Hemoglobin A<sub>1c</sub> Variability Metrics Predict Coronary
        Artery Calcium and Cardiovascular Events in Type 1
        Diabetes:
                    </span>
                    The CACTI Study</h1>
                    <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Horton WB, Snell-Bergeon JK. Hemoglobin A<sub>1c</sub> Variability Metrics Predict Coronary Artery Calcium and Cardiovascular Events
                            in Type 1 Diabetes: The CACTI Study. J Clin Endocrinol Metab. 2023 Jun 16;108(7):e444-e449. doi: 10.1210/ clinem/dgad019.
                        </p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/Magazine-edit-13-3-24.jpg" alt="feature-img">
                            </div>
                           <p>
                            Interventions that decrease mean glucose have reduced
        rates of micro- and macrovascular complications in type 1
        diabetes (T1D). However, the difference in cardiovascular
        risk between people with T1D and the general population
        endures, suggesting that factors beyond hemoglobin
        A<sub>1c</sub> (HbA<sub>1c</sub>) normalization drive cardiovascular outcomes.
                           </p>
                           <p>
                            Horton et al analyzed data from the Coronary
        Artery Calcification in Type 1 Diabetes (CACTI) Study
        (ClinicalTrials. gov Identifier: NCT00005754) to determine
        whether metrics of HbA<sub>1c</sub> variability predicted CAC
        volume, pericardial adipose tissue (PAT) volume, and/or
        CVD events in people with type 1 diabetes.
                           </p>
                           <p>The authors used linear regression to analyze the
                            relationship of several HbA<sub>1c</sub> metrics to anatomic CVD
                            risk factors and then used Cox regression to model their
                            relationship to incident CVD events in the CACTI Study
                            (ClinicalTrials.gov Identifier: NCT00005754).
                        </p>
                        <P>In linear regression models adjusted for age, sex, and
                            T1D duration, baseline HbA<sub>1c</sub> (b=0.3998, p=0.0236), mean
                            HbA<sub>1c</sub> (b=0.5385, p=0.0109), and HbA<sub>1c</sub> SD (b=1.1521,
                            p=0.0068) were each positively associated with square
                            root transformed coronary artery calcium volume.
                            Conversely, only mean HbA<sub>1c</sub> (b=1.659, p=0.0048)
                            positively associated with pericardial adipose tissue
                            volume.
                        </P>
            
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                In survival models adjusted for age, sex, and T1D duration,
        baseline HbA<sub>1c</sub> [hazard ratio (HR): 1.471, 95% CI: 1.257-1.721],
        mean HbA<sub>1c</sub> (HR: 1.850, 95% CI: 1.511-2.264), time-varying
        HbA<sub>1c</sub> (HR: 1.500, 95% CI: 1.236-1.821), and HbA<sub>1c</sub> SD (HR:
        1.665, 95% CI: 1.022- 2.711) each independently predicted
        CVD events over 14.3 ± 5.2 person-years of follow-up.
                            </p>
                            
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    The researchers showed a favorable correlation
        between baseline HbA<sub>1c</sub>, mean HbA<sub>1c</sub>, and
        HbA<sub>1c</sub> variability and square root converted CAC
        volume. After adjusting for age, sex, and the
        duration of type 1 diabetes, they also discovered
        that baseline HbA<sub>1c</sub>, mean HbA<sub>1c</sub> , time-varying
        HbA<sub>1c</sub>, and HbA<sub>1c</sub> variability all independently
        predicted incident CVD and CAD events in the
        CACTI type 1 diabetes cohort.<br>
        Even after adjusting for a number of known
        CVD risk variables, such as CAC, a measure
        of subclinical atherosclerosis and a powerful
        predictor of CVD events, these relationships
        with CVD and CAD events persisted for baseline
        HbA<sub>1c</sub>, mean HbA<sub>1c</sub>, and time-varying HbA<sub>1c</sub>.
        Various HbA<sub>1c</sub> metrics outside mean HbA<sub>1c</sub> are
        now being identified as risk factors for both
        microvascular disease and macrovascular
        disease in patients with type 1 diabetes,
        according to mounting data.<br>
        These metrics may represent novel yet
        potentially modifiable therapeutic targets. All
        things considered, the findings imply that a
        suitable treatment plan for persons with type
        1 diabetes may involve sustaining a HbA<sub>1c</sub> level
        that is within target range and largely stable
        over time.<br>
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        T1D, type 1 diabetes; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>, CAC, coronary artery calcium;
        CVD, cardiovascular disease; SD, standard deviation; HR, hazard ratio
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>14</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">Impact of Severe Hypoglycemia Requiring
                        Hospitalization on Mortality in People with Type 1
                        Diabetes:
                    </span>
                    A National Retrospective Observational Cohort Study
                </h1>
                    <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Moser O, Rafferty J, Eckstein ML, Aziz F, Bain SC, Bergenstal R, Sourij H, Thomas RL. Impact of severe hypoglycemia
                            requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study. Diabetes
                            Obes Metab. 2023 Aug;25(8):2243-2254. doi: 10.1111/dom.15102.
                        </p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-25.jpg" alt="feature-img">
                            </div>
                            <p>
                                The aim of this study was to assess whether the number
        of severe hypoglycemia episodes in people with Type
        1 Diabetes (T1D) is associated with increased risk of allcause
        mortality.
                            </p>
                                <p>
                                    To this end, Moser et al., conducted a national
                                    retrospective observational cohort study in people
                                    with T1D (diagnosed between 2000 and 2018). Clinical,
                                    comorbidity and demographic variables were assessed
                                    for impact on mortality for people with no, one, two
                                    and three or more episodes of severe hypoglycemia
                                    requiring hospitalization. The time to death (all-cause
                                    mortality) from the timepoint of the last episode of
                                    severe hypoglycemia was modelled using a parametric
                                    survival model.
                                </p>
                                <p>
                                    In all, total of 8224 people had a T1D diagnosis in Wales
        during the study period. The mortality rate (95%
        confidence interval [CI]) was 6.9 (6.1-7.8) deaths/1,000
        person- years (crude) and 15.31 (13.3-17.63) deaths/1,000
        person-years (age-adjusted) for those with no occurrence
        of severe hypoglycemia requiring hospitalization.
                                </p>
            
                    
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                For those with one episode of severe hypoglycemia
                                requiring hospitalization the mortality rate (95% CI) was
                                24.9 (21.0-29.6; crude) and 53.8 (44.6-64.7) deaths/1,000
                                person-years (age-adjusted), for those with two episodes
                                of severe hypoglycemia requiring hospitalization it was
                                28.0 (23.1-34.0; crude) and 72.8 (59.2-89.5) deaths/ 1,000
                                person-years (age-adjusted), and for those with three
                                or more episodes of severe hypoglycemia requiring
                                hospitalization it was 33.5 (30.0- 37.3; crude) and 86.3
                                (71.7-103.9) deaths/ 1000 person years (age-adjusted;
                                p&lt;
                                0.001). A parametric survival model showed that
                                having two episodes of severe hypoglycemia requiring
                                hospitalization was the strongest predictor for time to
                                death (accelerated failure time coefficient 0.073 [95%
                                CI 0.009-0.565]), followed by having one episode of
                                severe hypoglycemia requiring hospitalization (0.126
                                [0.036-0.438]) and age at most recent episode of severe
                                hypoglycemia requiring hospitalization (0.917 [0.885-
                                0.951]).
                            </p>
                           
                           
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    This report highlighted the elevation in risk of
        mortality in people with T1D experiencing
        episodes of severe hypoglycemia requiring
        hospitalization.<br>
        The strongest predictor for time to death, in
        other words, the variable with the TR that
        differed most from 1, was having two or more
        episodes of severe hypoglycemia requiring
        hospitalization. Intriguingly, the parametric
        survival model showed that even one episode of
        severe hypoglycemia requiring hospitalization
        increased the risk of earlier death compared
        with having no episodes, and the risk
        increased further with two episodes of severe
        hypoglycemia requiring hospitalization.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        RWD, real-world data; RCT, randomized controlled trial; RWE, real-world evidence
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>15</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>
                
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main">                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon.png" alt="">
                        </a>
                    </div>
                    <div class="row align-items-center p-100 d-flex justify-content-center">
                        <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                        <div class="col-6 align-content-center"><div class="dark-line"></div></div>
                        <div class="col-3 sanofi-logo"><img src="img/sanofi-logo-black.png" alt=""></div>
                    </div>
                </header>
                <div class="article-head">
                    <h1 class="headline"><span class="bold">Type 1 Diabetes and Risk of Heart Failure:
                        A Systematic Review and Meta-analysis</span>
                       </h1>
                    <hr>
                    <div class="subheader">
                        <p class="primary-col">Source: Haji M, Erqou S, Fonarow GC, Echouffo-Tcheugui JB. Type 1 diabetes and risk of heart failure: A systematic reviewand metaanalysis.
                            Diabetes Res Clin Pract. 2023 Jun 24;202:110805. doi: 10.1016/j.diabres.2023.110805.</p>
                    </div>
                </div>
                <article>
                    <div class="row">
                        <div class="col-lg-6 col-sm-12">
                            <div class="feature-img">
                                <img src="./img/magazine-edit-13-3-26.jpg" alt="feature-img">
                            </div>
                            <p>
                                Robust data on type 1 diabetes (T1DM) and the risk of
        heart failure (HF) is scarce. In order to address current
        gaps in the literature, Haji et al performed a systematic
        review and meta-analysis of extant observational data
        on the association between type 1 diabetes and risk of
        incident heart failure.
                            </p>
                                <p>
                                    The authors searched PubMed and EMBASE for relevant
        studies, abstracted data on HF incidence rate and
        adjusted relative risk (aRR) for T1DM, type 2 diabetes
        (T2DM) and controls, and pooled incidence rates and
        aRRs for HF across studies.
                                </p>
                                <p>
                                    Four studies including 61,885 T1DM patients, 4,599,213
        non-diabetic controls, and 248,021 T2DM patients (three
        studies) were included. The pooled average proportions
        of men were 56%, 54%, and 55%, for T1DM, T2DM, and
        controls, respectively. The corresponding pooled average
        participants’ ages were 40, 65 and 57 years, respectively.
                                </p>
                        </div>
            
                        <div class="col-lg-6 col-sm-12">
                            <p>
                                Over a 1 to 12 years follow-up, 1,378, 3,993, 18,945 HF
        events occurred among individuals with T1DM, T2DM,
        and controls, yielding pooled HF incidence rates of 5.8
        (95%CI: 4.1-7.6), 10.0 (95% CI: 6.1-13.9), 2.3 (95% CI: 1.5-
        3.2) per 1,000 person-years, respectively. Compared to
        controls, T1DM patients had a 3-fold higher HF risk (aRR
        3.4, 95% CI 2.71-4.26). The RR of HF was ~ 5-fold higher in
        women (aRR: 4.9, 95% CI: 4.1-5.9) vs. 3-fold higher in men
        (aRR: 3.0, 95% CI: 2.2-4.0).
                            </p>
                           
                            <div class="purple-quote primary-bg">
                                <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                                <h3>Conclusion</h3>
                                <p>
                                    This study shows substantial higher absolute
        and relative risks of heart failure among patients
        with type 1 diabetes compared to those without
        diabetes. Given the younger age of the type 1
        diabetes versus type 2 diabetes cohorts in this
        study, the age-adjusted absolute heart failure
        risk in type 1 diabetes is likely higher than that
        observed in type 2 diabetes. This study reveals
        the paucity data on link between type 1 diabetes
        and heart failure in racial/ ethnically diverse
        samples, thus the need for further studies,
        especially given that the risk of heart failure
        related to type 1 diabetes may vary across racial/
        ethnic groups.<br>
        Such studies should also collect more detailed
        data on the control of diabetes and the
        accompanying cardiovascular risk factors. The
        results also highlight the importance of a more
        active heart failure prevention among patients
        with type 1 diabetes.
                                </p>
                            </div>
                            
                        </div>
                    </div>
                    
                    <div class="article-footer">
                        <div class="row">
                            <div class="col-lg-6 col-sm-12">
                                <div class="ref-rating">
                                    <p>
                                        T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; HF, heart
        failure; CI, confidence interval; aRR, adjusted relative risk
                                    </p>                    
                                </div>
                                <div class="rating">
                                    <p>How do you rate this article?</p>
                                    <div class="row px-4">
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                        <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_1_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                                    </div>
                                    <div class="rating-bar">
                                        <img src="./img/rating-1-5.png" alt="">
                                    </div>  
                                </div>
                            </div>
                        </div>
                    </div>
                </article>
                </div>
                <footer class="footer">
                    <div class="pages-header-footer">
                        <div class="row d-flex justify-content-center">
                            <div class="col-1 p-0">
                                <div class="pagination d-flex justify-content-center">
                                    <p>16</p>
                                </div>
                            </div>
                            <div class="col-7 align-content-center p-0">
                                <div class="dark-line"></div>
                            </div>
                            <div class="col-4 d-flex justify-content-center align-items-center p-0">
                                <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                            </div>
                        </div>
                    </div>       
            </footer>
          </div>
          <div class="carousel-item">
            <div class="main bg-end">
                
                <header class="pages-header-footer pages-h-f-white">
                    <div class="home-icon">
                        <a type="button" href="#carouselExampleControls" data-bs-target="#carouselExampleControls" data-bs-slide-to="0" class="active">
                            <img src="./img/home-icon-white.png" alt="">
                        </a>
                    </div>
                <div class="logo">
                    <img src="./img/sanofi-logo-white.png" alt="">
                </div>    
                </header>
               <div class="center-img">
                <img src="./img/Diabetes-360-emagazine.png" alt="">
               </div>
               <footer>
                <p class="end-footer">
                    SANOFI Egypt:<br>
                    3, EL Massaneh St., Zeitoun, Cairo, Egypt, P.O. BOX: 1486<br>
                    Tel.: +202 22860000- 22860060<br>
                    Fax: +202 22860107- 2286012<br><br>
                    Promocode MAT-EG-2400429
                </p>
            </footer>
                </div>
          </div>
          <button class="carousel-control-prev" type="button" data-bs-target="#carouselExampleControls" data-bs-slide="prev">
            <img src="./img/prev.png" alt="Previous">
            <span class="visually-hidden">Previous</span>
          </button>
          <button class="carousel-control-next" type="button" data-bs-target="#carouselExampleControls" data-bs-slide="next">
            <img src="./img/next.png" alt="Next">
            <span class="visually-hidden">Next</span>
          </button>
        </div>
        
      </div>
      
</div>


    <script src="./js/bootstrap.bundle.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.3/umd/popper.min.js"></script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/js/bootstrap.min.js"></script>
    <script src="https://code.jquery.com/jquery-3.3.1.slim.min.js"></script>
    
</body>
</html>